Home › Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization
 

Keywords :   


Lexicon Announces Focus On Late-Stage Development Programs And Preparation For Commercialization

2014-02-05 07:12:10| drugdiscoveryonline News Articles

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today it is focusing its resources on its late-stage drug development programs, principally LX4211 for diabetes and telotristat etiprate (LX1032) for carcinoid syndrome, and preparation for the transition to commercialization

Tags: development focus programs preparation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.114 ver. 6
23.11120
23.11 3rd tour DOUBLE STAR Blu-ray
23.11PSA8_
23.11/nd
23.11
23.11 #49
23.115in1UP
More »